Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Van der Ploeg AT, Reuser AJJ (2008) Lysosomal storage disease 2–Pompe′s disease. Lancet 372:1342–1352
Case LE, Koeberl DD, Young SP, Bali D, De Armey SM, Mackey J, Kishnani PS (2008) Improvement with ongoing enzyme replacement therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 95:233–235
Ghosh P, Dahms NM, Kornfeld S (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4:202–212
Joshi PR, Glaeser D, Schmidt S, Vorgerd M, Winterholler M, Eger K, Zierz S, Deschauer M Molecular genetic characterization of German patients with late-onset glycogen storage disease type II. J Inherit Metab Dis, PMID: 18607768 (in press)
Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676
Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 61:307–330
Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN et al (1998) Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79:69–72
Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL et al (2005) Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem 280:6780–6791
Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin YS, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmüller H, Schoser BGH (2007) Late-onset Pompe disease: clinical and neurophysiological spectrum of 38 patients with a long-term follow-up in 18 patients. Neuromuscul Disord 17:698–706
Pompe JC (1932) Over idiopathische hypertrofie van het hart. Ned Tijdsch Geneesk 76:304–311
Rossi M, Parenti G, Della CR, Romano A, Mansi G, Agovino T et al (2007) Long-term enzyme replacement therapy for Pompe disease with recombinant human alphaglucosidase derived from Chinese hamster ovary cells. J Child Neurol 22:565–573
Schoser BGH, Müller-Höcker J, Gempel K, Horvath R, Pongratz D, Lochmüller H, Muller-Felber W (2007) Glycogen storage disease type 2: clinic-pathological phenotype revisited. Neuropathol Appl Neurol 33:544–559
Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II (GSDII)/Pompe disease. Neurotherapeutics 5:569–578
Van der Beek NAME, Hagemans MLC, Reuser AJJ, Hop WCJ, Van der Ploeg AT, Van Doorn PA, Wokke JHJ (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19:113–117
Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF et al (2004) Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 55:495–502
Winkel LP, Hagemans ML, Van Doorn PA, Loonen MC, Hop WJ, Reuser AJ et al (2005) The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–884
Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ (1993) Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268:2223–2231